TW68, Cryptochromes stabilizer, regulates fasting blood glucose level inob/oband fat-induced diabetic mice

• DOI: 10.1101/2023.07.13.548861
• Publication Date: 2023-07-14T04:00:48Z
• Authors: Saliha Surme; Cagla Ergun; Seref Gul; Yasemin Kubra Akyel; Zeynep Melis Gul; Onur Ozcan; Ozgecan Savlug Ipek; Busra Aytul Akarlar; Nurhan Ozlu; Ali Cihan Taskin; Metin Turkay; Ahmet Ceyhan Gören; Ibrahim Baris; Nuri Ozturk; Mustafa Guzel; Cihan Aydin; Alper Okyar; Ibrahim Halil Kav...

AbstractCryptochromes (CRYs), transcriptional repressors of the circadian clock in mammals, inhibit cAMP production when glucagon activates G-protein coupled receptors. Therefore, molecules that modulate CRYs have the potential to regulate gluconeogenesis. In this study, we discovered a new molecule called TW68 that interacts with the primary pockets of mammalian CRY1/2, leading to reduced ubiquitination levels and increased stability. In cell-based circadian rhythm assays using U2OS:Bmal1-dLuccells, TW68 extended the period length of the circadian rhythm. Additionally, TW68 decreased the transcriptional levels of two genes,Phosphoenolpyruvate carboxykinase 1(PCK1) andGlucose-6-phosphatase(G6PC), which play crucial roles in glucose biosynthesis during glucagon-induced gluconeogenesis in HepG2 cells. Oral administration of TW68 in mice showed good tolerance, a good pharmacokinetic profile, and remarkable bioavailability. Finally, when administered to fastingob/oband fat-induced diabetic animals, TW68 reduced blood glucose levels by enhancing CRY stabilization and subsequently decreasing the transcriptional levels ofPck1andG6pc. These findings collectively demonstrate the antidiabetic efficacy of TW68in vivo, suggesting its therapeutic potential for controlling fasting glucose levels in the treatment of type 2diabetes mellitus.